Winrevair, the first activin signaling inhibitor therapy for PAH, is recommended for use in combination with other PAH therapies in adult patients with WHO Functional Class II to III, to improve exercise capacity.
The recommendation by the Committee for Medicinal Products for Human Use (CHMP) is based on data from the Phase III STELLAR trial, which showed that adding Winrevair to existing therapy significantly improved exercise capacity, measured by the six-minute walk distance (6MWD). Patients on Winrevair walked an average of 40.8m farther at 24 weeks than those on placebo. The drug also reduced the risk of death or PAH clinical worsening events by 84%, a secondary outcome that sets it apart from existing therapies.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.